Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Breaking News
Crash closes part of NC 55 at Triangle Expressway toll road near Morrisville
Program
On WRAL Monday at 6: Known carcinogens hiding in your childâs classroom? WRAL Investigates why some local schools are refusing to take action
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Exelixis Inc
(NQ:
EXEL
)
25.81
-0.07 (-0.27%)
Streaming Delayed Price
Updated: 2:20 PM EDT, Aug 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Exelixis Inc
< Previous
1
2
3
4
5
Next >
3 Stocks to Buy for a Soft Landing, If There Is One
August 15, 2024
Recent economic data is reigniting talk about a soft landing for the economy; here are three stocks to consider if a soft landing materializes
Via
MarketBeat
Topics
Economy
Exposures
Economy
Interest Rates
Exelixis Announces Second Quarter 2024 Financial Results and Provides Corporate Update
August 06, 2024
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces U.S. Food and Drug Administration (FDA) Accepted the Supplemental New Drug Application for Cabozantinib for Patients with Advanced Neuroendocrine Tumors
August 06, 2024
From
Exelixis, Inc.
Via
Business Wire
Exelixis to Release Second Quarter 2024 Financial Results on Tuesday, August 6, 2024
July 23, 2024
From
Exelixis, Inc.
Via
Business Wire
Exelixis to Present at the William Blair 44th Annual Growth Stock Conference
May 28, 2024
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA
May 20, 2024
From
Exelixis, Inc.
Via
Business Wire
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May
May 07, 2024
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update
April 30, 2024
From
Exelixis, Inc.
Via
Business Wire
Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024
April 16, 2024
From
Exelixis, Inc.
Via
Business Wire
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March
February 27, 2024
From
Exelixis, Inc.
Via
Business Wire
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
February 14, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NYSE:PFE),(NASDAQ:BTAI),(NYSE:BMY) EQNX::TICKER_END
Via
FinancialNewsMedia
Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update
February 06, 2024
From
Exelixis, Inc.
Via
Business Wire
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
February 14, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February
February 01, 2024
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024
January 25, 2024
From
Exelixis, Inc.
Via
Business Wire
Exelixis to Release Fourth Quarter and Fiscal Year 2023 Financial Results on Tuesday, February 6, 2024
January 23, 2024
From
Exelixis, Inc.
Via
Business Wire
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
January 22, 2024
From
Bristol Myers Squibb
Via
Business Wire
European Patent Office Rules in Favor of Exelixis on Formulation Patent Covering CABOMETYX® (cabozantinib) Tablets
January 18, 2024
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces Preliminary Fiscal Year 2023 Financial Results, Provides 2024 Financial Guidance, and Outlines Key Priorities and Milestones for 2024
January 07, 2024
From
Exelixis, Inc.
Via
Business Wire
Exelixis to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 8, 2024
January 02, 2024
From
Exelixis, Inc.
Via
Business Wire
Exelixis 2023 R&D Day: Science & Strategy to be Webcast on December 12, 2023
December 07, 2023
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces Initiation of the STELLAR-305 Phase 2/3 Pivotal Trial Evaluating Zanzalintinib in Combination with Pembrolizumab in Patients with Previously Untreated Recurrent or Metastatic Head and Neck Cancer
December 04, 2023
From
Exelixis, Inc.
Via
Business Wire
Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma
December 04, 2023
From
Arcus Biosciences
Via
Business Wire
Improving Survival Rates: Biotech Innovations in Pancreatic Cancer Treatment
November 29, 2023
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:EXEL),(NASDAQ:MRTX),(NYSE:LLY),(NASDAQ:PNT) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Death
Exposures
Death
Exelixis to Present at the Piper Sandler 35th Annual Healthcare Conference on November 28, 2023
November 21, 2023
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces Encouraging Results from Expansion Cohort of Phase 1b STELLAR-001 Trial Evaluating Zanzalintinib in Patients with Advanced Kidney Cancer at IKCS 2023
November 10, 2023
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces Third Quarter 2023 Financial Results and Provides Corporate Update
November 01, 2023
From
Exelixis, Inc.
Via
Business Wire
Global Cancer Vaccines Market Share Is Expected To Reach $19.27 Billion By 2030
October 25, 2023
EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NASDAQ:JAZZ),(NASDAQ:EXEL),(NASDAQ:AMGN),(NASDAQ:REGN) EQNX::TICKER_END
Via
FinancialNewsMedia
Detailed Results from Phase 3 CABINET Pivotal Trial Evaluating Cabozantinib in Advanced Neuroendocrine Tumors Presented at ESMO 2023
October 22, 2023
From
Exelixis, Inc.
Via
Business Wire
Exelixis to Release Third Quarter 2023 Financial Results on Wednesday, November 1, 2023
October 18, 2023
From
Exelixis, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.